课题基金 / 基金详情

NKT cells and tumour immunosurveillance

NKT cells and tumour immunosurveillance
NKT细胞与肿瘤免疫监视
批准号:
nhmrc : 194252
负责人:
Prof Dale Godfrey
金额:
$5.37万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2002
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2002-01-01 至 2002-12-31

项目摘要

项目成果

Prof Dale Godfrey的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Although the immune system has the ability to reject tumours, this sometimes does not occur, leading to cancer. There are many different types of cells that make up the immune system, including some which respond very early, called natural killer (NK) and NKT cells. These cells are the first line of defence against some tumours, although we do not understand how they recognise and respond to tumour cells. The aim of this project is to investigate the functional importance of both NK and NKT cells in response to a range of different tumour types, including melanoma (skin cancer), lung carcinoma, breast carcinoma and sarcoma (connective tissue tumour). We will test the importance of each of these subsets by injecting these tumours into mice that have specific deficiencies in NK and-or NKT cells. If the NK or NKT cells are important, the tumours should grow more effectively when these immune cells are absent. We will also be able to put NK and-or NKT cells back into the mice to show directly that they are responsible for tumour rejection. Using a modification of this cell transfer approach, we will be able to inhibit special molecules that are normally produced by these cells that help them interact with other cells, and also help them attack the tumour cells. Collectively, the approaches outlined in this application allow us to determine which types of cells are important in response to a broad range of different tumour types, and also should tell us how these cells are able to attack the tumours. This information will be invaluable for the development of new strategies to use the patients immune system to attack cancer (known as immuno-therapy).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CD1C-LIPID-REACTIVE T CELLS
  • 批准号:
    DP210103064
  • 项目类别:
    Discovery Projects
  • 资助金额:
    $34.38万
  • 财政年份:
    2021
  • 负责人:
    Prof Dale Godfrey
  • 依托单位:
Unrestricted antigen recognition by T lymphocytes
  • 批准号:
    DP170104386
  • 项目类别:
    Discovery Projects
  • 资助金额:
    $29.95万
  • 财政年份:
    2017
  • 负责人:
    Prof Dale Godfrey
  • 依托单位:
Unconventional T cells in health and disease
  • 批准号:
    nhmrc : GNT1117766
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $86.39万
  • 财政年份:
    2017
  • 负责人:
    Prof Dale Godfrey
  • 依托单位:
Unconventional T cells in health and disease
  • 批准号:
    nhmrc : 1117766
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $59.07万
  • 财政年份:
    2017
  • 负责人:
    Prof Dale Godfrey
  • 依托单位:
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
  • 批准号:
    82371634
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵福军
  • 依托单位:
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
  • 批准号:
    82371801
  • 项目类别:
    面上项目
  • 资助金额:
    47.00万元
  • 批准年份:
    2023
  • 负责人:
    周海波
  • 依托单位:
脐带间充质干细胞微囊联合低能量冲击波治疗神经损伤性ED的机制研究
  • 批准号:
    82371631
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    卢慕峻
  • 依托单位: